LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

Home・Akciju saraksts・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Slēgts

4.43 -9.59

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.33

Max

4.47

Galvenie mērījumi
By Trading Economics
Ienākumi	5.5M -28M
Pārdošana	8.2M 13M
Peļņas marža	-208.694
Darbinieki	172
EBITDA	8.7M -27M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+190.35% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-26M 229M
Iepriekšējā atvēršanas cena	14.02
Iepriekšējā slēgšanas cena	4.43

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

3.17 / 3.4644 Atbalsts un pretestība

Voyager Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 13. marts 19:08 UTC

Galvenie ziņu notikumi

TotalEnergies Shutting Production in Qatar, Iraq Amid Fighting in Middle East

2026. g. 13. marts 18:48 UTC

Peļņas

Galvenie tirgus virzītāji

Capricor Therapeutics Falls on Wider-Than-Expected 4Q Loss

2026. g. 13. marts 17:10 UTC

Galvenie ziņu notikumi

Week Ahead for FX, Bonds: Central Bank Decisions in Focus After Jump in Energy Prices

2026. g. 13. marts 17:10 UTC

Galvenie ziņu notikumi

Week Ahead for FX, Bonds: Central Bank Decisions -2-

2026. g. 13. marts 16:47 UTC

Galvenie ziņu notikumi

The Week in Oil: Hormuz Crisis Pushes Brent Above $100

2026. g. 13. marts 22:27 UTC

Tirgus saruna

Galvenie ziņu notikumi

Bahrain Faces Uncertainty But Has Support Amid War, S&P Says -- Market Talk

2026. g. 13. marts 22:13 UTC

Tirgus saruna

Galvenie ziņu notikumi

Saudi Arabia Seen as Able to Weather Iran Conflict, S&P Says -- Market Talk

2026. g. 13. marts 22:04 UTC

Tirgus saruna

Galvenie ziņu notikumi

Emirate of RAK Outlook Stable Despite Iran War, S&P Says -- Market Talk

2026. g. 13. marts 22:00 UTC

Iegādes, apvienošanās, pārņemšana

Trump Administration Set to Receive $10 Billion Fee for Brokering TikTok Deal -- WSJ

2026. g. 13. marts 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 13. marts 20:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Financial Services Roundup: Market Talk

2026. g. 13. marts 20:02 UTC

Tirgus saruna

Canada Rate Hike in 2026 Would Mark 'Extraordinarily Bad' Policy -- Market Talk

2026. g. 13. marts 19:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Posts Weekly Gains As Middle East Conflict Drags On -- Market Talk

2026. g. 13. marts 19:35 UTC

Galvenie ziņu notikumi

Oil Prices Hover Near $100. India Asks Iran to Allow 23 Tankers Through Strait of Hormuz. -- Barrons.com

2026. g. 13. marts 19:00 UTC

Tirgus saruna

U.S. Natural Gas Futures Settle Lower -- Market Talk

2026. g. 13. marts 18:49 UTC

Galvenie ziņu notikumi

The Iran War Could Upend AI. Here's How. -- Barrons.com

2026. g. 13. marts 18:24 UTC

Galvenie ziņu notikumi

Impact of Middle East Conflict on TotalEnergies Activities

2026. g. 13. marts 18:00 UTC

Galvenie ziņu notikumi

Is War Good For the Economy? -- WSJ

2026. g. 13. marts 17:23 UTC

Tirgus saruna

U.S. Oil Rig Count Rises by 1 to 412 -- Market Talk

2026. g. 13. marts 16:46 UTC

Tirgus saruna

Galvenie ziņu notikumi

European Indexes End Week Lower as Oil Takes Driving Seat -- Market Talk

2026. g. 13. marts 16:38 UTC

Galvenie ziņu notikumi

Higher Oil Prices Could Bring a Global Economic Shock. This Is the Number to Watch. -- Barrons.com

2026. g. 13. marts 16:34 UTC

Iegādes, apvienošanās, pārņemšana

EQT Says It Received Around CHF21 Bln in Total From Galderma Share Sales

2026. g. 13. marts 16:33 UTC

Iegādes, apvienošanās, pārņemšana

EQT Receives Proceeds of Around CHF1.3B From Sell-Down

2026. g. 13. marts 16:32 UTC

Iegādes, apvienošanās, pārņemšana

EQT Completes Exit From Galderma

2026. g. 13. marts 16:20 UTC

Tirgus saruna

Galvenie ziņu notikumi

Financial Services Roundup: Market Talk

2026. g. 13. marts 16:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 13. marts 16:15 UTC

Galvenie ziņu notikumi

Why Exxon and Energy Stocks Finally Started to Rise This Week as the Iran War Escalated -- Barrons.com

2026. g. 13. marts 16:11 UTC

Tirgus saruna

Carney Tries to Put Dismal Canada Jobs Data in Context -- Market Talk

2026. g. 13. marts 16:00 UTC

Galvenie ziņu notikumi

Here's Where the U.S. Economy Is Most Vulnerable to Iran War -- WSJ

2026. g. 13. marts 15:48 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Turn Higher as Supply Worries Remain -- Market Talk

Salīdzinājums

Cenas izmaiņa

Voyager Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

190.35% augšup

Prognoze 12 mēnešiem

Vidējais 14.14 USD 190.35%

Augstākais 25 USD

Zemākais 8 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 8 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

3.17 / 3.4644Atbalsts un pretestība

Recent bearish events outweigh bullish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.